ARTHRITIS, PSORIATIC

This study tests whether guselkumab can reduce spine-related symptoms and inflammation in people with active psoriatic arthritis. About 411 participants who have not used biologic drugs before will receive either guselkumab or a placebo. The main goal is to see if symptoms like b…

This study follows over 1,300 people with psoriatic arthritis to see how long they continue taking guselkumab or IL-17 inhibitor medications in routine care. Researchers will track joint swelling and tenderness, and record when patients start and stop these drugs. The goal is to …

This study tests whether guselkumab, an injected drug, can reduce joint pain and swelling in people with active psoriatic arthritis who did not get enough relief from or could not tolerate a prior TNF-blocker. About 453 adults will receive either guselkumab or a placebo for 24 we…

This study tests a drug called guselkumab in people with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. The goal is to see if the drug can reduce symptoms and prevent joint damage from getting worse. About 1054 adults who have not responde…

This study tests the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished a previous sonelokimab study will receive the drug as a shot under the skin. The goal is to see if the drug remains safe and he…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to under 18 who have Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a prior study and shown benefit from the drug. The main goal is to track …

This study tests an experimental drug called JNJ-77242113 (icotrokinra) in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The goal is to see if the drug reduces joint pain, swelling, and skin symptoms better than a placebo. Participants …

This study tests a new injectable drug called sonelokimab for people with active psoriatic arthritis who haven't tried biologic treatments before. About 960 adults will receive either the drug or a placebo to see if it improves joint pain and swelling. The goal is to control the …